These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21781116)

  • 1. A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ.
    O'Nuallain B; Klyubin I; Mc Donald JM; Foster JS; Welzel A; Barry A; Dykoski RK; Cleary JP; Gebbink MF; Rowan MJ; Walsh DM
    J Neurochem; 2011 Oct; 119(1):189-201. PubMed ID: 21781116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils.
    O'Nuallain B; Freir DB; Nicoll AJ; Risse E; Ferguson N; Herron CE; Collinge J; Walsh DM
    J Neurosci; 2010 Oct; 30(43):14411-9. PubMed ID: 20980598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aβ dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies.
    O'Malley TT; Oktaviani NA; Zhang D; Lomakin A; O'Nuallain B; Linse S; Benedek GB; Rowan MJ; Mulder FA; Walsh DM
    Biochem J; 2014 Aug; 461(3):413-26. PubMed ID: 24785004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies that target pathological assemblies of Abeta.
    Lambert MP; Velasco PT; Chang L; Viola KL; Fernandez S; Lacor PN; Khuon D; Gong Y; Bigio EH; Shaw P; De Felice FG; Krafft GA; Klein WL
    J Neurochem; 2007 Jan; 100(1):23-35. PubMed ID: 17116235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide.
    Welzel AT; Williams AD; McWilliams-Koeppen HP; Acero L; Weber A; Blinder V; Mably A; Bunk S; Hermann C; Farrell MA; Ehrlich HJ; Schwarz HP; Walsh DM; Solomon A; O'Nuallain B
    PLoS One; 2012; 7(11):e50317. PubMed ID: 23209707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secreted amyloid β-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity.
    Welzel AT; Maggio JE; Shankar GM; Walker DE; Ostaszewski BL; Li S; Klyubin I; Rowan MJ; Seubert P; Walsh DM; Selkoe DJ
    Biochemistry; 2014 Jun; 53(24):3908-21. PubMed ID: 24840308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Brain-Derived Aβ Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP.
    Wang Z; Jackson RJ; Hong W; Taylor WM; Corbett GT; Moreno A; Liu W; Li S; Frosch MP; Slutsky I; Young-Pearse TL; Spires-Jones TL; Walsh DM
    J Neurosci; 2017 Dec; 37(49):11947-11966. PubMed ID: 29101243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice.
    Tucker S; Möller C; Tegerstedt K; Lord A; Laudon H; Sjödahl J; Söderberg L; Spens E; Sahlin C; Waara ER; Satlin A; Gellerfors P; Osswald G; Lannfelt L
    J Alzheimers Dis; 2015; 43(2):575-88. PubMed ID: 25096615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease.
    Li S; Jin M; Liu L; Dang Y; Ostaszewski BL; Selkoe DJ
    Acta Neuropathol Commun; 2018 Nov; 6(1):121. PubMed ID: 30409172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization.
    Klyubin I; Betts V; Welzel AT; Blennow K; Zetterberg H; Wallin A; Lemere CA; Cullen WK; Peng Y; Wisniewski T; Selkoe DJ; Anwyl R; Walsh DM; Rowan MJ
    J Neurosci; 2008 Apr; 28(16):4231-7. PubMed ID: 18417702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomes neutralize synaptic-plasticity-disrupting activity of Aβ assemblies in vivo.
    An K; Klyubin I; Kim Y; Jung JH; Mably AJ; O'Dowd ST; Lynch T; Kanmert D; Lemere CA; Finan GM; Park JW; Kim TW; Walsh DM; Rowan MJ; Kim JH
    Mol Brain; 2013 Nov; 6():47. PubMed ID: 24284042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau and Amyloid β Protein in Patient-Derived Aqueous Brain Extracts Act Concomitantly to Disrupt Long-Term Potentiation
    Ondrejcak T; Klyubin I; Hu NW; O'Malley TT; Corbett GT; Winters R; Perkinton MS; Billinton A; Prenderville JA; Walsh DM; Rowan MJ
    J Neurosci; 2023 Aug; 43(32):5870-5879. PubMed ID: 37491315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers.
    Townsend M; Shankar GM; Mehta T; Walsh DM; Selkoe DJ
    J Physiol; 2006 Apr; 572(Pt 2):477-92. PubMed ID: 16469784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation.
    Sehlin D; Englund H; Simu B; Karlsson M; Ingelsson M; Nikolajeff F; Lannfelt L; Pettersson FE
    PLoS One; 2012; 7(2):e32014. PubMed ID: 22355408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease Aβ in vivo.
    Klyubin I; Ondrejcak T; Hayes J; Cullen WK; Mably AJ; Walsh DM; Rowan MJ
    Philos Trans R Soc Lond B Biol Sci; 2014 Jan; 369(1633):20130147. PubMed ID: 24298149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer's brain.
    Li S; Selkoe DJ
    J Neurochem; 2020 Sep; 154(6):583-597. PubMed ID: 32180217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.
    Shankar GM; Li S; Mehta TH; Garcia-Munoz A; Shepardson NE; Smith I; Brett FM; Farrell MA; Rowan MJ; Lemere CA; Regan CM; Walsh DM; Sabatini BL; Selkoe DJ
    Nat Med; 2008 Aug; 14(8):837-42. PubMed ID: 18568035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.
    Klyubin I; Walsh DM; Lemere CA; Cullen WK; Shankar GM; Betts V; Spooner ET; Jiang L; Anwyl R; Selkoe DJ; Rowan MJ
    Nat Med; 2005 May; 11(5):556-61. PubMed ID: 15834427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
    Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
    PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid-β oligomer specificity mediated by the IgM isotype--implications for a specific protective mechanism exerted by endogenous auto-antibodies.
    Lindhagen-Persson M; Brännström K; Vestling M; Steinitz M; Olofsson A
    PLoS One; 2010 Nov; 5(11):e13928. PubMed ID: 21085663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.